Loss of p16 in recurrent malignant mixed müllerian tumors of the uterus

International Journal of Gynecological Cancer

Volumn 16, Issue 3, 2006, Pages 1354-1357

  Robinson Bennett, B ^a   Belch, R Z ^b   Han, A C ^c  

^a University of Texas Medical Branch School of Medicine   (United States)

^b READING HOSPITAL AND MEDICAL CENTER   (United States)

^c Department of Pathology and Laboratory Medicine ^*  (United Arab Emirates)

Author keywords

Malignant mixed m llerian tumor; Oncoprotein; p53; Peritoneal

Indexed keywords

CADHERIN; CERB B2 PROTEIN; ONCOPROTEIN; P CADHERIN; PARAFFIN; PROTEIN P16; PROTEIN P53; UNCLASSIFIED DRUG;

ABDOMINAL HYSTERECTOMY; AGED; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; DIFFERENTIATION; EPITHELIUM; FEMALE; GENE EXPRESSION PROFILING; HISTOGENESIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MIXED MULLERIAN TUMOR; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; RECURRENT CANCER; SALPINGOOOPHORECTOMY; SARCOMA; TUMOR SUPPRESSOR GENE; UTERUS CANCER;

AGED; AGED, 80 AND OVER; CADHERINS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; GENE DELETION; GENES, P16; HUMANS; MIXED TUMOR, MULLERIAN; NEOPLASM RECURRENCE, LOCAL; RECEPTOR, ERBB-2; TUMOR SUPPRESSOR PROTEIN P53; UTERINE NEOPLASMS;

EID: 33745091103     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00411.x     Document Type: Article

References (34)

1. Ng JS Han AC Edelson MI Rosenblum NG. Oncoprotein profiles of primary peritoneal malignant mixed mullerian tumors. Int J Gynecol Cancer 2003 13 : 870 4.
2. Garamvoelgyi E Guillou L Gebhard S Salmeron M Seematter FJ Hadji MH. Primary malignant mixed mullerian tumor (metaplastic carcinoma) of the female peritoneum. A clinical, pathologic, and immunohistochemical study of three cases and a review of the literature. Cancer 1994 74 : 854 63.
3. Shen DH Khoo US Xue WC et al. Primary peritoneal malignant mixed mullerian tumors. A clinicopathologic, immunohistochemical, and genetic study. Cancer 2001 91 : 1052 60.
4. Sreenan JJ Hart WR. Carcinosarcomas of the female genital tract. A pathologic study of 29 metastatic tumors: further evidence for the dominant role for the epithelial component and the conversion theory of histogenesis. Am J Surg Pathol 1995 19 : 666 74.
5. Jin Z Ogata S Tamura G et al. Carcinosarcomas (malignant mullerian mixed tumors) of the uterus and ovary: a genetic study with special reference to histogenesis. Int J Gynecol Pathol 2003 22 : 368 73.
6. McCluggage WG. Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas. Int J Gynecol Cancer 2002 12 : 687 90.
7. Kounelis S Jones MW Papadaki H Bakker A Swalsky P Finkelstein SD. Carcinosarcomas (malignant mixed Mullerian tumors) of the female genital tract: Comparative molecular analysis of epithelial and mesenchymal components. Hum Pathol 1998 29 : 82 7.
8. Liggett WH Sidransky D. Role of the p16 tumor suppressor gene in cancer. J Clin Oncol 1998 16 : 1197 206.
9. Berchuck A Kohler MF Marks JR Wiseman R Boyd J Bast RC. The p53 tumor suppressor gene frequently is altered in gynecologic cancers. Am J Obstet Gynecol 1994 170 : 246 52.
10. Liu FS Kohler MF Marks JR Bast RC Boyd J Berchuck A. Mutation and overexpression of the p53 tumor suppressor gene frequently occurs in uterine and ovarian sarcomas. Obstet Gynecol 1994 83 : 118 24.
11. Swisher EM Gown AM Skelly M et al. The expression of epidermal growth factor receptor, Her-2/Neu, p53, and Ki-67 antigen in uterine malignant mixed mesodermal tumors and adenosarcoma. Gynecol Oncol 1996 70 : 81 8.
12. Blom R Guerrieri C Stal O Malmstrom H Sullivan S Simonsen E. Malignant mixed mullerian tumors of the uterus: a clinicopathologic DNA flow cytometric, p53, and mdm-2 analysis of 44 cases. Gynecol Oncol 1998 68 : 18 24.
13. Costa MJ Vogelsang J Young LJT. P53 gene mutation in female genital tract carcinosarcomas (malignant mixed Mullerian tumors): a clincopathologic study of 74 cases. Mod Pathol 1994 7 : 619 27.
14. Szukala SA Marks JR Burchette JL Elbendary AA Krigman HR. Co-expression of p53 by epithelial and stromal elements in carcinosarcoma of the female genital tract: an immunohistochemical study of 19 cases. Int J Gynecol Cancer 1999 8 : 131 6.
15. Swisher EM Gown AM Skelly M et al. The expression of epidermal growth factor receptor, HER-2/Neu, p53, and Ki-67 antigen in uterine malignant mixed mesodemal tumors and adenosarcoma. Gynecol Oncol 1996 60 : 81 8.
16. Koukoulis GK Patriarca C Gould VE. Adhesion molecules and tumor metastasis. Hum Pathol 1998 29 : 889 92.
17. Stefansson IM Salvesen HB Akslen LA. Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer. J Clin Oncol 2004 22 : 1242 52.
18. Savage KJ Monti S Kutok JL et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003 102 : 3871 9.
19. Ginos MA Page GP Michalowicz BS et al. Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck. Cancer Res 2004 64 : 55 63.
20. Saxena A Shrim LM Dean M Ali IU. Comparative molecular genetic profiles of anaplastic astrocytomas/glioblastomas multiforme and their subsequent recurrences. Oncogene 1999 18 : 1385 90.
21. Lossos IS Czerwinski DK Alizadeh AA et al. Prediction of survival in diffuse large B cell lymphoma based on the expression of six genes. N Engl J Med 2004 350 : 1828 37.
22. Lynch TJ Bell DW Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 2004 350 : 2129 39.
23. Cunningham D Humblet Y Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan refractory metastatic colorectal cancer. N Engl J Med 2004 351 : 337 45.
24. Newby JC Johnston SR Smith IE Dowsett M. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res 1997 3 : 1643 51.
25. Ramondetta LM Burke TW Jhingran A et al. A phase II trial of cisplatin, ifosfamide, and mesna in patients with advanced or recurrent uterine malignant mixed mullerian tumors with evaluation of potential molecular targets. Gynecol Oncol 2003 90 : 529 36.
26. Maloney KW McGavran L Odom LF Hunger SP. Acquisition of p16ink4a and p15ink4b gene abnormalities between initial diagnosis and relapse in children with acute lymphoblastic leukemia. Blood 1999 93 : 2380 5.
27. Primdahl H von der Maase H Sorensen FB Wolf H Orntoft TF. Immunohistochemical study of the expression of cell cycle regulating proteins at different stages of bladder cancer. J Cancer Res Clin Oncol 2002 128 : 295 301.
28. Finegan MM Han AC Edelson MI Rosenblum NG. p16 expression in squamous lesions of the female genital tract. J Mol Histol 2004 35 : 111 4.
29. Child FJ Scarisbrick JJ Calonje E Orchard G Russell-Jones R Whittaker SJ. Inactivation of tumor suppressor genes p15 (INK4b) and p16 (INK4a) in primary cutaneous B cell lymphomas. J Invest Dermatol 2002 118 : 941 8.
30. Maruya S Kurotaki H Shimoyama N Kaimor M Shinkawa H Hagihashi S. Expression of p16 protein and hypermethylation status of its promoter gene in adenoid cystic carcinoma of the head and neck. ORL J Otorhinolaryngol Relat Spec 2003 65 : 26 32.
31. Chatterjee SJ George B Goebell PJ et al. Hyperphosphorylation of pRb: a mechanism for RB tumour suppressor pathway inactivation in bladder cancer. J Pathol 2004 203 : 762 70.
32. Graff JR Gabrielson E Fujii H Baylin SB Herman JG. Methylation patterns of the E-cadherin 5′ CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression. J Biol Chem 2000 275 : 2727 32.
33. Han S Ahn SH Park K et al. P16INK4a protein expression is associated with poor survival of the breast cancer patient after CMF chemotherapy. Breast Cancer Res Treat 2001 70 : 205 12.
34. Savage DG Antman KH. Drug therapy: imatinib mesylate - a new oral targeted therapy. N Engl J Med 2002 346 : 683 93.